Contents
21 November 2018
Vol 10, Issue 468
Vol 10, Issue 468
Research Articles
- Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo
Post-exposure highly potent human monoclonal antibodies target Andes hantavirus glycoprotein in a hamster hantavirus cardiopulmonary syndrome model.
- Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis
Aberrant hepatocyte Notch activation is required for development of NASH-associated fibrosis, and Notch inhibition ameliorates obesity-induced liver disease.
- Long-term mechanical function and integration of an implanted tissue-engineered intervertebral disc
Tissue-engineered intervertebral discs demonstrate long-term functional integration in rat and goat disc replacement models.
- Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma
Inhalation of a Janus kinase 1 inhibitor suppressed lung inflammation without systemic side effects in rodent models of asthma.
Editors' Choice
- Not just uninhibited: Interneurons and seizure onset
Optogenetic study in vivo demonstrates that different types of interneurons show consistently elevated but distinct firing patterns in the period preceding seizure onset in a rodent model of epilepsy.
- 10,368 first dates: Microfluidic T cell matchmaking
Coencapsulation of T cells and target cells into arrays of subnanoliter droplets improves the identification of functional T cell receptors.
- Noncanonical DNA modification revealed in glioblastoma
ALKBH1 promotes glioblastoma by controlling the N6-methyladenine DNA modification on hypoxia response genes.
Erratum
About The Cover
ONLINE COVER Hampering Hantavirus. There are no targeted treatments for hantavirus cardiopulmonary syndrome, which can be caused by different types of hantaviruses that circulate in rodents. To develop therapeutics for this potentially fatal disease, Garrido et al. isolated memory B cells from people who had survived infection with Andes hantavirus (pictured here). Antibodies isolated from these B cells were tested for hantavirus neutralization in vitro. Two potently neutralizing antibodies protected hamsters from fatal infection, even when the antibodies were given three days after the virus. These antibodies could potentially be administered to patients infected with hantavirus as post-exposure therapy. [CREDIT: JAMES CAVALLINI/SCIENCE SOURCE]
